Coordinating Antibiotics, Test Development Could Shorten Approval Times, US FDA Says
Executive Summary
In a new draft guidance, the agency recommends antimicrobial drug developers and sponsors of antimicrobial susceptibility tests coordinate their regulatory submissions to get their products on the market together faster.
You may also be interested in...
Coordinated Antimicrobial Drug/Device Development Addressed In FDA Final Guidance
In its bid to fight antimicrobial resistance, the agency has finalized a 2016 guidance on how novel antibiotic developers can coordinate with antimicrobial susceptibility test-makers to ensure their products come to market at about the same time. The agency recommends using its pre-submission process for a more efficient review.
Antibiotic Pipeline Profile: Narrowing The Spectrum Of Drug Activity
Development is most advanced in C. difficile infection, but US FDA's exploration of pathways to expedite single pathogen treatments could spur earlier-stage QIDP projects targeting Staphylococcus and Pseudomonas species.
UN Countries Make Bold Pledges On AMR, Including Funding For R&D Into New Drugs and Diagnostics
During the high-level UN meeting on Sept. 21, all 193 member countries will sign a declaration in which they pledge to take concrete action on tackling antimicrobial resistance, including providing resources for research into new drugs, vaccines and diagnostics, and ensuring good stewardship of antibiotic use in both humans and animals.